We are live on ! Find out more
STLNW

Starling Oncology Warrant
STLNW

21 hedge funds and large institutions have $5.52M invested in Starling Oncology Warrant in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.64% less ownership

Funds ownership: 11.37% → 10.74% (-0.64%)

14% less capital invested

Capital invested by funds: $6.44M → $5.52M (-$927K)

19% less funds holding

Funds holding: 26 → 21 (-5)

83% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 6

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
21
Holders Change
-5
Holders Change %
-19.23%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
2
Closed
6
Calls
$989K
Puts
–
Net Calls
+$989K
Net Calls Change
-$836K

Top Buyers

Rank Fund Capital Flow
1
USPCM
Union Square Park Capital Management
New York
+$165K

Top Sellers

Rank Fund Capital Flow
1
QGA
Q Global Advisors
Texas
-$168K
2
GCL
Glazer Capital LLC
New York
-$156K
3
KLC
Kent Lake Capital
Nevada
-$63K
4
RCM
Radcliffe Capital Management
Pennsylvania
-$58.6K
5
PSAMP
P. Schoenfeld Asset Management (PSAM)
New York
-$43K

STLNW Hedge Fund Activity: Q3 2021 in Review

21 of the 5,729 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology Warrant (STLNW) for Q3 2021, worth a combined $5.52M — down 14% from $6.44M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of STLNW and 1 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 0 added.

The largest buyer was Union Square Park Capital Management, opening a new position worth an estimated $165K. The largest seller was Q Global Advisors, exiting entirely with an estimated $168K sold.

  • 21 institutional investors held Starling Oncology Warrant (STLNW) as of Q3 2021, down from 26 in Q2 2021.
  • Funds reported $5.52M of Starling Oncology Warrant stock for Q3 2021, down 14% quarter-over-quarter.
  • 1 fund opened new Starling Oncology Warrant positions in Q3 2021 and 6 closed out, a net change of -5 holders.
  • The largest Starling Oncology Warrant buyer in Q3 2021 was Union Square Park Capital Management, an estimated $165K added.
  • The largest Starling Oncology Warrant seller in Q3 2021 was Q Global Advisors, an estimated $168K sold.

Based on aggregated 13F filings for Q3 2021.